CTLA4 and neoplasm: We next evaluated the in vivo potency of anti-PD-1 and anti-CTLA-4 mAbs as monotherapies, combination and MEDI8500 in non tumour-bearing humanized mice, using GvHD development as a potential predictor of toxicity and potency of these immunotherapies and combinations.